Longeveron Inc. (LGVN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Longeveron Inc. (LGVN) closed at USD 1.73 on 2026-10-14, a change of -81.4 % over the past year, with a market capitalization of USD 4.78M.

Longeveron Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Longeveron Inc. key figures

Previous close

USD 1.73 (2026-10-14)

1-year change

-81.4 %

Market cap

USD 4.78M

Enterprise value

USD -4.71M

P/E ratio (trailing)

-0.22

P/E ratio (forward)

-0.98

EPS (trailing)

-6.69

EPS (forward)

-1.53

PEG ratio

n/a

Price to book

0.46

Revenue growth

-9.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.62

Employees

38

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Longeveron Inc. and compare it with other stocks.